Cochlear dysfunction as an early biomarker of cognitive decline in normal hearing and mild hearing loss.

IF 4 Q1 CLINICAL NEUROLOGY Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2024-02-01 eCollection Date: 2024-01-01 DOI:10.1002/dad2.12467

Vicente Medel, Paul H Delano, Chama Belkhiria, Alexis Leiva, Cristina De Gatica, Victor Vidal, Carlos F Navarro, Simon San Martín, Melissa Martínez, Christine Gierke, Ximena García, Mauricio Cerda, Rodrigo Vergara, Carolina Delgado, Gonzalo A Farías

{"title":"Cochlear dysfunction as an early biomarker of cognitive decline in normal hearing and mild hearing loss.","authors":"Vicente Medel, Paul H Delano, Chama Belkhiria, Alexis Leiva, Cristina De Gatica, Victor Vidal, Carlos F Navarro, Simon San Martín, Melissa Martínez, Christine Gierke, Ximena García, Mauricio Cerda, Rodrigo Vergara, Carolina Delgado, Gonzalo A Farías","doi":"10.1002/dad2.12467","DOIUrl":null,"url":null,"abstract":"Introduction: Age-related hearing loss is an important risk factor for cognitive decline. However, audiogram thresholds are not good estimators of dementia risk in subjects with normal hearing or mild hearing loss. Here we propose to use distortion product otoacoustic emissions (DPOAEs) as an objective and sensitive tool to estimate the risk of cognitive decline in older adults with normal hearing or mild hearing loss.Methods: We assessed neuropsychological, brain magnetic resonance imaging, and auditory analyses on 94 subjects > 64 years of age.Results: We found that cochlear dysfunction, measured by DPOAEs-and not by conventional audiometry-was associated with Clinical Dementia Rating Sum of Boxes (CDR-SoB) classification and brain atrophy in the group with mild hearing loss (25 to 40 dB) and normal hearing (<25 dB).Discussion: Our findings suggest that DPOAEs may be a non-invasive tool for detecting neurodegeneration and cognitive decline in the older adults, potentially allowing for early intervention.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"16 1","pages":"e12467"},"PeriodicalIF":4.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10835081/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.12467","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Age-related hearing loss is an important risk factor for cognitive decline. However, audiogram thresholds are not good estimators of dementia risk in subjects with normal hearing or mild hearing loss. Here we propose to use distortion product otoacoustic emissions (DPOAEs) as an objective and sensitive tool to estimate the risk of cognitive decline in older adults with normal hearing or mild hearing loss.

Methods: We assessed neuropsychological, brain magnetic resonance imaging, and auditory analyses on 94 subjects > 64 years of age.

Results: We found that cochlear dysfunction, measured by DPOAEs-and not by conventional audiometry-was associated with Clinical Dementia Rating Sum of Boxes (CDR-SoB) classification and brain atrophy in the group with mild hearing loss (25 to 40 dB) and normal hearing (<25 dB).

Discussion: Our findings suggest that DPOAEs may be a non-invasive tool for detecting neurodegeneration and cognitive decline in the older adults, potentially allowing for early intervention.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

耳蜗功能障碍是正常听力和轻度听力损失患者认知能力下降的早期生物标记。

导言与年龄有关的听力损失是认知能力下降的一个重要风险因素。然而，对于听力正常或轻度听力损失的受试者来说，听力图阈值并不能很好地估计痴呆风险。在此，我们建议使用失真产物耳声发射（DPOAE）作为一种客观、灵敏的工具，来估计听力正常或轻度听力损失的老年人认知能力下降的风险：我们对 94 名年龄大于 64 岁的受试者进行了神经心理学、脑磁共振成像和听觉分析评估：结果：我们发现，在轻度听力损失（25 至 40 dB）和听力正常的人群中，通过 DPOAE（而非传统听力测定法）测量的耳蜗功能障碍与临床痴呆评级方框总和（CDR-SoB）分类和脑萎缩有关（讨论：我们的研究结果表明，DPOAE（而非传统听力测定法）测量的耳蜗功能障碍与临床痴呆评级方框总和（CDR-SoB）分类和脑萎缩有关：我们的研究结果表明，DPOAEs 可能是检测老年人神经变性和认知能力下降的一种非侵入性工具，有可能实现早期干预。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Medicine-Psychiatry and Mental Health

CiteScore

7.80

自引率

7.50%

发文量

101

审稿时长

8 weeks

期刊介绍： Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.